Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=3;spage=1054;epage=1055;aulast=Shah |
| _version_ | 1797824269173915648 |
|---|---|
| author | Chirag Shah Kishore Sonkusare |
| author_facet | Chirag Shah Kishore Sonkusare |
| author_sort | Chirag Shah |
| collection | DOAJ |
| first_indexed | 2024-03-13T10:36:25Z |
| format | Article |
| id | doaj.art-cf66294e876045ba839af0e53482fe95 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-03-13T10:36:25Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-cf66294e876045ba839af0e53482fe952023-05-18T06:11:44ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892023-01-017131054105510.4103/IJO.IJO_2609_22Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degenerationChirag ShahKishore Sonkusarehttp://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=3;spage=1054;epage=1055;aulast=Shah |
| spellingShingle | Chirag Shah Kishore Sonkusare Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration Indian Journal of Ophthalmology |
| title | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_full | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_fullStr | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_full_unstemmed | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_short | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_sort | response to commentary on a prospective randomized parallel group double blind multicenter study to compare the efficacy safety and immunogenicity of lupin s ranibizumab with lucentis in patients with neovascular age related macular degeneration |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=3;spage=1054;epage=1055;aulast=Shah |
| work_keys_str_mv | AT chiragshah responsetocommentaryonaprospectiverandomizedparallelgroupdoubleblindmulticenterstudytocomparetheefficacysafetyandimmunogenicityoflupinsranibizumabwithlucentisinpatientswithneovascularagerelatedmaculardegeneration AT kishoresonkusare responsetocommentaryonaprospectiverandomizedparallelgroupdoubleblindmulticenterstudytocomparetheefficacysafetyandimmunogenicityoflupinsranibizumabwithlucentisinpatientswithneovascularagerelatedmaculardegeneration |